We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Use of a Silkworm (Bombyx mori) Larvae By-Product for the Treatment of Atopic Dermatitis: Inhibition of NF-κB Nuclear Translocation and MAPK Signaling.
- Authors
Fan, Meiqi; Choi, Young-Jin; Wedamulla, Nishala Erandi; Zhang, Qun; Kim, Seong Wan; Bae, Sung Moon; Seok, Young-Seek; Kim, Eun-Kyung
- Abstract
Atopic dermatitis (AD) is a long-lasting inflammatory skin disease that contributes to the global health burden and impacts 10–20% of the world's population. In this study, we determined the anti-AD effect of a by-product of silkworm (Bombyx mori) larval powder, strain Yeonnokjam (SLPY), as a sustainable, natural source for the development of therapeutic agents for AD. HaCaT cells were used to assess the in vitro anti-inflammatory activity of SLPY, and a 1-chloro-2,4-dinitrobenzene (DNCB)-induced mouse model was used to study the in vivo anti-AD effects. SLPY treatment downregulated the expression of the inflammatory cytokines TNF-α, IL1β, IL-8, and Cox-2 in stimulated HaCaT cells. Similarly, the topical application of SLPY in DNCB-treated mice downregulated the expression of inflammatory cytokines and proteins while ameliorating the clinical features of AD. Further, SLPY treatment inhibited the nuclear translocation of NF-κb p65, thereby supporting the efficacy of SLPY in the treatment of AD.
- Subjects
BIOLOGICAL models; IN vitro studies; CYTOKINES; INTERLEUKINS; IN vivo studies; ANIMAL experimentation; NF-kappa B; CELLULAR signal transduction; MOTHS; ATOPIC dermatitis; RESEARCH funding; MITOGEN-activated protein kinases; MICE
- Publication
Nutrients, 2023, Vol 15, Issue 7, p1775
- ISSN
2072-6643
- Publication type
Article
- DOI
10.3390/nu15071775